Effect of alpha-linolenic acid on the metabolism of omega-3 and omega-6 polyunsaturated fatty acids and histamine release in RBL-2H3 cells.
We examined the effect of alpha-linolenic acid (18:3 (n-3)) pretreatment on the metabolism of omega-3 and omega-6 polyunsaturated fatty acids and histamine content and release of RBL-2H3 cells. RBL-2H3 cells grew without reduction in number when incubated with subculture media for 3 d and then placed again in serum-free medium with bovine serum albumin (BSA) and epidermal growth factor (EGF). Cholesterol pullulan (10 micrograms/ml) emulsified alpha-linolenic acid (20 micrograms/ml) was recommended as an additional form serum free medium. We determined the fatty acid composition in all neutral lipids, free fatty acids and all phospholipids in alpha-linolenic acid-treated cells. In all cases the concentration of alpha-linolenic acid and docosahexenoic acid (DHA, 22:6 (n-3)) was increased, while linolenic acid (18:2 (n-6)) was slightly and arachidonic acid (20:4 (n-6)) was markedly decreased. Content of histamine in alpha-linolenic acid-treated cells was remarkably lower than that of untreated cells. Accordingly, net histamine release stimulated by antigen or A23187 was also markedly decreased in the alpha-linolenic acid-treated cells, as was the percent histamine release stimulated by antigen. Results from our in vitro experiment suggest that the anti-allergic effect of alpha-linolenic acid may be caused either by the decrease in histamine content or by inhibition of the release of chemical mediator resulting from changes in the fatty acid composition.
Kawasaki
M
M
National Institute of Health Sciences, Tokyo, Japan.
Toyoda
M
M
Teshima
R
R
Sawada
J
J
Saito
Y
Y
D000818:Animals; D001491:Basophils / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D000001:Calcimycin / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002784:Cholesterol / Q000737:chemistry; D002851:Chromatography, High Pressure Liquid; D004042:Dietary Fats, Unsaturated / Q000378:metabolism*; D004140:Dinitrophenols / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004655:Emulsions; D004815:Epidermal Growth Factor / Q000737:chemistry; D015525:Fatty Acids, Omega-3 / Q000378:metabolism*; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated / Q000378:metabolism*; D005936:Glucans / Q000737:chemistry; D006241:Haptens / Q000494:pharmacology; D006634:Histamine H1 Antagonists / Q000494:pharmacology; D006636:Histamine Release / Q000187:drug effects*; D015471:Leukemia, Basophilic, Acute / Q000473:pathology; D050356:Lipid Metabolism; D010743:Phospholipids / Q000378:metabolism; D051381:Rats; D012710:Serum Albumin, Bovine / Q000737:chemistry / Q000494:pharmacology; D014407:Tumor Cells, Cultured; D017962:alpha-Linolenic Acid / Q000494:pharmacology*
D004042:Dietary Fats, Unsaturated; D004140:Dinitrophenols; D004655:Emulsions; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D005231:Fatty Acids, Unsaturated; D005936:Glucans; D006241:Haptens; D006634:Histamine H1 Antagonists; D010743:Phospholipids; C034638:dinitrophenyl-bovine serum albumin; D017962:alpha-Linolenic Acid; D012710:Serum Albumin, Bovine; D000001:Calcimycin; D004815:Epidermal Growth Factor; D002784:Cholesterol